INTRODUCTION
Chronic GVHD (cGVHD) is associated with significant morbidity and mortality. 1, 2 In addition to being a leading cause of late treatment-related deaths among allogeneic recipients, cGVHD is associated with deficits in quality of life that parallel systemic autoimmune diseases. The cGVHD Consortium was established to test the 2005 NIH working group definitions for cGVHD severity, 3 and to determine other prognostic measures that predict overall and disease-free survival, non-relapse mortality (NRM) and functional impairment among patients with cGVHD. 4 Early data from the Consortium have demonstrated prognostic utility of the NIH global cGVHD severity score at enrollment, 5 and the poor prognosis of the 'overlap' subtype of cGVHD when both acute and cGVHD manifestations are present concurrently. 6 The prevalence of comorbid illness in patients with cGVHD, and the influence of comorbidity burden upon subsequent functional and survival outcomes, have been examined in only a single previous study of 100 patients. 7 Previous studies have evaluated the role of comorbidities present at the time of transplantation and shown that greater comorbidity burden is associated with higher rates of NRM and inferior OS compared with patients who have fewer comorbidities. The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is an example of a standardized way of measuring comorbidities in a population of hematopoietic cell transplant (HCT) candidates. 8 This scale measures a mixture of pre-existing diagnoses and organ dysfunction at the time of HCT, assigning weights to different comorbidities to derive a composite score. This scale has demonstrated prognostic importance among patients receiving transplants for AML and MDS, 9 including in reduced intensity conditioning settings, 10 for CLL, 11 and for NHL and MM. 12, 13 However, it has not been applied to patients in the post-transplant setting. The Functional Comorbidity Index (FCI) is a comorbidity scale that was developed in a population of patients with spine disease and controls, 14 with physical function rather than mortality as an outcome. This index has also been found to predict future physical function in a population of patients with adult respiratory distress syndrome 15 and has been used to assess HCT patients with cGVHD. 7 The prognostic value of the HCT-CI has not yet been examined in the setting of cGVHD. cGVHD imposes unique physiological and functional vulnerabilities through the effects of the disease itself and the toxicities of the immunosuppressive treatments used to manage cGVHD. Knowledge of the contribution that factors such as comorbidity make to the interpretation of survival outcomes in cGVHD has the potential to strengthen study design and interpretation. This knowledge may also inform risk assessment and survival prognostication for newly diagnosed cGVHD patients, which may have direct utility in the clinic. Thus, we determined whether a measure of comorbidity could provide prognostic information independent of cGVHD characteristics. There are currently no validated scales for measuring comorbidity in patients with cGVHD, so we used the HCT-CI and FCI to determine comorbidities at the time of enrollment into the cGVHD Consortium and tested their associations with overall mortality and NRM. Finally, we aimed to evaluate whether these scales supplemented information provided by the NIH cGVHD Global Severity Scale.
MATERIALS AND METHODS
The cGVHD Consortium began patient accrual in 2007 and has prospectively followed recipients with cGVHD in a multicenter, observational study. As previously published data 18 have demonstrated discrepancies in the way that the elements of the HCT-CI are captured between sites, this analysis was restricted to participants from Fred Hutchinson Cancer Research Center where two clinicians performed all the chart reviews in order to ensure uniformity of comorbidity scoring. The protocol was approved by the Institutional Review Board at Fred Hutchinson Cancer Research Center, and all subjects provided informed consent in accordance with the Declaration of Helsinki. Enrolled patients were allogeneic HCT recipients age 2 or older with cGVHD, diagnosed by the NIH consensus criteria, requiring systemic immunosuppressive therapy. The cohort includes patients with either classic cGVHD or overlap syndrome. Cases were classified as incident (enrollment o3 months after cGVHD diagnosis) or prevalent (enrollment 3 or more months after cGVHD diagnosis but o3 years after HCT). At enrollment and every 6 months thereafter, physicians and patients report standardized information on cGVHD organ involvement and symptoms. Incident cases had an additional assessment time-point of 3 months after enrollment. cGVHD global severity (mild, moderate severe) was determined from individual organ scoring provided by clinicians using the NIH consensus scoring.
Comorbidity grading
A complete list of comorbidities was systematically abstracted from medical records for all patients at transplant and at the time of cGVHD cohort enrollment based on comprehensive history and physical exam documentation and available test results. Extracted data included comorbidities found in the FCI and the HCT-CI. These definitions adhered to the respective FCI and HCT-CI comorbidity definitions with a few exceptions (for example, pulmonary dysfunction was assessed by recent PFTs, as in the HCT-CI definition, although the FCI definition uses a patient history of ARDS, COPD or emphysema).
An FCI score was calculated for each patient based on work by Groll et al. 14 The FCI measures 18 different comorbidities, though this instrument was developed in part to predict physical function rather than mortality, and has not been studied extensively within the transplant setting. In this scale, which includes several comorbidities distinct from the HCT-CI (such as osteoporosis, visual and hearing impairment and degenerative disc disease), each comorbidity is assigned a score of 1 and comorbidities are summed to determine a total score (theoretical range 0-18).
An HCT-CI was calculated for each patient based on work by Sorror et al. 7 The HCT-CI is a scale that includes 17 comorbidities and was developed to be used at the time of transplantation. Comorbidities include prior diagnoses (for example, prior solid malignancy, cardiac disease), current diagnoses (for example, active infection, diabetes, obesity, depression) and ongoing organ dysfunction (for example, renal, pulmonary, hepatic). Each comorbidity, if present, is assigned a weighted score from 1 to 3, and some comorbidities are assigned different scores according to severity (for example, moderate pulmonary dysfunction is assigned a 2 and severe pulmonary dysfunction is assigned a 3). The weighted comorbidities are summed to determine a total score (theoretical range 0-26).
Statistical methods
Descriptive characteristics of the cohort are reported. The weights and aggregation algorithms recommended by the scales' developers were applied to yield an FCI and an HCT-CI score at two time-points: at the time of transplantation and at the time of enrollment into the cohort. Paired t-tests were used to determine whether scores changed between the two time-points. NIH cGVHD global severity scoring at the time of enrollment was calculated from information reported on the case report forms completed by providers. The association of the proportion of involved patients for each comorbidity item between pretransplant and enrollment was evaluated by McNemar's test. 16 Logistic regression models were used to test associations between individual comorbidities and HCT-CI quartiles.
For the purposes of model construction, cutpoints were used according to previously reported prognostic importance (platelet count o100 000/mL vs X100 000/mL; Karnofsky performance score o80 vs X80; age at transplantation X50 vs o50; months between transplant and enrollment o12 vs X12). Both incident and prevalent cases were included.
The HCT-CI was included in the models with published weights as a continuous variable.
The criteria for scoring liver or lung disease as a comorbidity in the HCT-CI overlap with organ-specific scoring criteria for these manifestations on the NIH cGVHD severity scale. Both the HCT-CI and the NIH cGVHD severity scale define the presence and severity of pulmonary dysfunction by abnormalities of the FEV1 or DLCO, though the cutpoints are different between scales and the NIH scale incorporates the Lung Function Score (a composite of these two variables). For liver, both the HCT-CI and the NIH cGVHD severity scale define moderate and severe liver dysfunction by abnormalities of the bilirubin or transaminases, though again the cutpoints are different between the two scales. As of the overlap between the HCT-CI and the NIH scale for pulmonary and liver dysfunction, we also tested a version of the HCT-CI that excluded lung and liver dysfunction in calculating the HCT-CI score.
Univariate and multivariate Cox regression models were constructed to examine associations between the comorbidity indices at the time of cohort enrollment and subsequent survival, adjusting for all known and available risk factors. Models were constructed with and without the NIH global severity score in order to determine the relative prognostic importance of the comorbidity scales vs the NIH global severity score. OS was calculated from the time of enrollment, with patients censored at the date last known alive. NRM was defined as death before relapse, with relapse treated as a competing event. The c-statistic was calculated for the comorbidity scores as a measure of their predictive ability for the outcomes of interest. The c-statistic varies from 0.5-1.0, with 0.5 indicating no predictive ability and higher numbers indicating better prediction. Statistical analyses were conducted using SAS software, Version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS

Population characteristics
Baseline characteristics of the 239 patients included in this analysis are displayed in Table 1a (transplant characteristics) and Table 1b (additional variables at the time of enrollment into the cGVHD cohort). Most recipients had a history of prior acute I-IV GVHD (74%). Global cGVHD severity by NIH criteria was mild or less in 8%, moderate in 54% and severe in 38% of recipients. Median follow-up of survivors was 32 months (range 0.6-55.0). Table 2 demonstrates the complete FCI and HCT-CI, at the assessment points. Three comorbidities in the FCI (peripheral vascular disease, visual impairment and hearing impairment) were not seen at the time of transplantation in any recipients. At the time of transplantation, comorbidities in the FCI seen in 410% of recipients included pulmonary disease (61%), upper gastrointestinal disease (31%), obesity (25%) and depression (22%). At the time of cohort enrollment, 13 comorbidities in the FCI increased in prevalence. Among these, pulmonary disease (69%), osteopenia/ osteoporosis (47%), upper gastrointestinal disease (52%), depression (24%) and diabetes (17%) were seen in 410% of recipients. The proportions of patients with osteopenia/osteoporosis (Po0.001), lung dysfunction (P ¼ 0.02), neurological disease (P ¼ 0.007), diabetes (Po0.001) and upper gastrointestinal disease (Po0.001) were significantly higher at enrollment than at the time of transplantation, and the proportion of patients with obesity (Po0.001) was significantly lower at enrollment than at the time of transplantation. The mean FCI score at the time of transplantation was 1.8 (range 0-8) and increased to 2.7 (range 0-7) at the time of cohort enrollment (Po0.001).
Prevalence of comorbidities according to the FCI
Prevalence of comorbidities according to the HCT-CI Prevalent comorbidities in the HCT-CI at the time of transplantation included moderate pulmonary dysfunction (41%), psychiatric disturbance (25%), severe pulmonary dysfunction (20%), prior solid tumor (13%) and obesity (11%) ( Table 2 ). Eight comorbidities in the HCT-CI were observed in o5% of patients. At the time of enrollment, seven comorbidities were seen in 10% or more of patients: severe pulmonary dysfunction (38%, nearly doubling from 20% at the time of transplantation), psychiatric disturbance (29%), moderate pulmonary dysfunction (31%), mild hepatic dysfunction (23%), diabetes (17%), infection (13%) and prior solid malignancy (13%). The proportions of patients with diabetes (Po0.001), mild hepatic dysfunction (Po0.001), infection (P ¼ 0.007) and severe pulmonary dysfunction (Po0.001) were significantly higher at cGVHD cohort enrollment than at the time of transplantation, and the proportions of patients with obesity (P ¼ 0.008), and moderate pulmonary dysfunction (P ¼ 0.03) were significantly lower at enrollment than at the time of transplantation. The mean HCT-CI weighted score at the time of transplantation was 2.6 (range 0-8) and increased to 3.7 (range 0-12) at the time of cohort enrollment (Po0.001). Table 3 depicts comorbidities in the HCT-CI at the time of cGVHD cohort enrollment, listed by quartiles of overall HCT-CI scores (0-2, 3, 4-5 and X6). The prevalence and number of comorbidities increased progressively across the score quartiles. For example, in the lowest quartile, one comorbidity (moderate pulmonary dysfunction) was seen in 420% of patients, whereas in the highest quartile, eight comorbidities were seen in 420% of patients, including one (severe pulmonary dysfunction) that was identified in more than half of the patients. The proportion of patients with specific comorbidities increased progressively across HCT-CI quartiles, including cardiac (P ¼ 0.001), inflammatory bowel disease (P ¼ 0.04), diabetes (P ¼ 0.001), psychiatric disturbance (Po0.001), mild hepatic dysfunction (P ¼ 0.02), infection (P ¼ 0.001), moderate/severe renal (Po0.001), severe pulmonary (Po0.001), prior solid tumor (Po0.001) and moderate/severe hepatic (Po0.001). Table 4 shows the prevalence of specific comorbidities in patients with a platelet count of X or o100 000 at the time of cohort enrollment. There was a significantly higher prevalence of infection in patients with a platelet count o100 000 than in patients with a platelet count X100 000 at the time of enrollment (29 vs 10%, P ¼ 0.001).
OS
The FCI at the time of cGVHD cohort enrollment was not predictive of OS in univariate or multivariate analysis (data not shown). Table 5 shows that higher HCT-CI scores at the time of cGVHD cohort enrollment were predictive for an increased risk of overall mortality (HR: 1.16:1.02-1.31, P ¼ 0.02) as a continuous variable in the multivariate model. Enrollment in the cGVHD cohort within the first year after transplant was an adverse prognostic factor (HR: 2.38:1.08-5.24, P ¼ 0.03), and lower Karnofsky performance score (o80) at enrollment was also predictive of subsequent higher risk of overall mortality (HR: 2.32:1.17-4.59, P ¼ 0.02). No other variables were statistically significant in the multivariate analysis. No interaction effect between HCT-CI and case type was observed (P ¼ 0.99), but a statistically significant interaction of the HCT-CI with platelet count was observed (P ¼ 0.003), such that higher HCT-CI scores were associated with an increased risk of overall mortality when the platelet count was o100 000/mL (HR: 2.01:1.20-3.35, P ¼ 0.01), but was observed between HCT-CI and case type (P ¼ 0.69), nor between HCT-CI and platelet count (P ¼ 0.12). After controlling for HCT-CI at the time of transplantation, higher HCT-CI change scores from the time of transplantation to cohort enrollment were still associated with an increased risk of NRM (HR: 1.22: 1.00-1.49, P ¼ 0.05).
Common elements in the HCT-CI and NIH cGVHD global severity scoring The NIH global severity score, includes liver and lung dysfunction, which together substantially determine the maximum global (3) 31 (13) 31 (13) severity score based on a previous Consortium analysis. 5 The HCT-CI also includes pulmonary and hepatic dysfunction, with both given weights up to 3. Because the NIH global severity score predicts mortality, we sought to determine whether these scales overlapped significantly with one another, and whether liver and lung dysfunction were responsible for the prognostic importance of the HCT-CI. We found that overlap existed between the HCT-CI and the NIH cGVHD severity scales at enrollment in the scoring of liver (correlation ¼ 0.61) and lung (correlation ¼ 0.61) dysfunction. We constructed a multivariate model that excluded the NIH severity score, and found that the significance of the HCT-CI was not enhanced (HR: 1.16, P ¼ 0.02), suggesting that the HCT-CI is an independent predictor. We calculated a version of the HCT-CI that excluded consideration of pulmonary and liver comorbidities. Although this version of the HCT-CI was significant in univariate analysis (HR: 1.19, P ¼ 0.02), it was not significant in a covariate-adjusted model (HR: 1.15, P ¼ 0.12). It is possible that the lack of significance of this version of the HCT-CI in the multivariate model may reflect lack of prevalence of the remaining comorbidities to provide sufficient power for this analysis. We also constructed a model that included pulmonary and liver comorbidity scores individually, without the HCT-CI, while controlling for other prognostic factors. In this model, neither pulmonary nor liver dysfunction was statistically associated with an increased risk of mortality (P ¼ 0.17 and P ¼ 0.19, respectively). These results suggest that the influence of the HCT-CI on mortality outcomes is not predominantly accounted for by pulmonary and liver dysfunction. In its complete form, the HCT-CI showed fair predictive ability for OS (c-statistic 0.63) and NRM (c-statistic 0.68) in our cGVHD population.
DISCUSSION
We examined the performance of two approaches to comorbidity assessment in patients with cGVHD. We found that one, the HCT-CI, predicted the risk of mortality when platelet counts were o100 000/mL but not when the platelet count was over 100 000/ mL while another, the FCI, was not associated with the risk of mortality. These results suggest that understanding comorbidity burden is important in patients with cGVHD because it has independent prognostic significance even after adjustment for cGVHD variables but that the choice of comorbidity measurement tool matters. We acknowledge that the prognostic significance of the HCT-CI is modest, and thus may not in its current construction be the most ideal measure of comorbidity in this patient population. Additionally, the finding of significance in patients with platelets less than but not more than 100 000 does not have intuitively obvious meaning, though the difference in prevalence of infection in these two groups may suggest one possible explanation. The HCT-CI was developed and validated for use at the time of transplantation and has not been examined previously in cGVHD, a condition for which there are no currently validated comorbidity scales. In our study of people with cGVHD, a HCT-CI captured at the time of enrollment into the cGVHD cohort predicted the risk of subsequent mortality. Whether comorbidity burden increases equally in patients with or without cGVHD is not Interaction of HCT-CI with platelet count noted; for plateletso100 000/mL and HCT-CI, HR 2.01 (1.20-3.35), P ¼ 0.01.
currently known, and should be examined in future studies to determine the proportion of comorbidity burden increase that can be attributed to cGVHD.
The HCT-CI places particular weight on substantial, objectively measured pulmonary dysfunction, a variable that has been identified as prognostically relevant in hematopoietic cell transplantation 17 but can also reflect cGVHD and is part of the calculation of cGVHD global severity. Liver dysfunction is also part of the global NIH severity score. Our analyses support the relevance of the HCT-CI independent of the NIH severity score, and suggest that the totality of the index, and not just commonly abnormal variables such as pulmonary and liver dysfunction, is prognostically relevant for patients with cGVHD.
Several caveats should be considered in generalizing our study findings. Children, ethnic and racial minorities are underrepresented. Patients with mild cGVHD requiring topical therapy only were not enrolled in the cohort. The HCT-CI, as previously noted, was not developed nor validated for a patient population with cGVHD. Additionally, HCT-CI scoring is complicated, laborious, based on specific laboratory tests for some organs, prone to inter-observer variability and requires training to ensure accuracy. 18 In our study, two clinicians did all the chart review to generate the HCT-CI scores. Currently, efforts are underway to ensure uniformity and consistency of HCT-CI scoring across institutions, which will allow a multicenter effort investigating the relationship of the comorbidities with outcomes after cGVHD.
Moving forward, we urge further investigations that could lead to a mechanistic understanding of physiologic vulnerability in patients with cGVHD. Though the original HCT-CI appears to be prognostically significant in a cGVHD population, the measure was not developed for use in this population and the prognostic strength of this measure in patients with cGVHD is modest. It is likely that additional work to develop and validate a new 'cGVHD-CI' will provide greater prognostic information for the cGVHD population.
One could also explore other measures of dysfunction for prognostic relevance that are not captured in traditional comorbidity scales. Examples of these include longitudinal patient-reported outcomes, 19 direct functional assessments such as cardiopulmonary exercise testing 20 or molecular markers of toxicity and aging 21 that might help to measure vulnerability 22 in this patient population. The knowledge derived from improved assessment of comorbidity can be applied in at least three ways. First, the inclusion of comorbidity scores can help isolate the effects of cGVHD and its treatment on morbidity and mortality, separate from the effects of concurrent conditions, thus improving the interpretation of findings in both observational studies and therapeutic trials. Second, comorbidity assessment can help tailor cGVHD therapies in order to avoid giving overly toxic therapies to patients who are unable to tolerate them. Last, knowledge of comorbidities may also help in constructing and targeting supportive care regimens to improve overall outcomes.
For now, we recommend further studies of comorbidity scoring at the time of cGVHD onset or at enrollment into a clinical trial in order to improve the prediction of outcomes in this patient population. We also recommend continued study of whether supportive care interventions or different cGVHD treatment approaches in low vs high comorbidity scoring patients might influence outcomes. We hope that studies of this kind will lead to improved OS in this vulnerable patient population. 
